26 Results for "

SERD

" in MedChemExpress (MCE) Product Catalog:
Products (26)

26 Results for "SERD" in MCE Product Catalog:

29
29 Publications Verification
Cat. No.: HY-12870
CAS No.: 1639042-08-2
Purity:  99.28%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

AZD9496 is an effective, selective estrogen receptor (ERα) antagonist with an IC50 of 0.28 nM. AZD9496 is an orally active, selective estrogen receptor degrader (SERD).
loading...
    loading...
29
29 Publications Verification
Cat. No.: HY-12870A
CAS No.: 1639042-28-6
Purity:  99.35%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

AZD9496 maleate is a potent and selective estrogen receptor (ERα) antagonist with IC50 of 0.28 nM. AZD9496 maleate is an orally bioavailable selective oestrogen receptor degrader (SERD).
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-19822
CAS No.: 722533-56-4
Synonyms: RAD1901
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-19822A
CAS No.: 1349723-93-8
Synonyms: RAD1901 dihydrochloride
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Elacestrant (RAD1901) dihydrochloride is an orally available and selective estrogen receptor degrader (SERD) with IC50s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER + breast cancer cell lines in vitro and in vivo .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-12864
CAS No.: 1365888-06-7
Purity:  99.85%
Synonyms: ARN-810; GDC-0810
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Brilanestrant (ARN-810; GDC-0810) is an orally bioavailable selective estrogen receptor degrader (SERD) with IC50 of 0.7 nM.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-133017
CAS No.: 2114339-57-8
Purity:  99.79%
Synonyms: SAR439859
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

SAR439859 (compound 43d) is an orally active, non-steroidal, and selective estrogen receptor degrader (SERD). SAR439859 is an effective ER antagonist with ER degradation activity, an EC50 of 0.2 nM. SAR439859 can show potent anti-tumor effects and limited cross-resistance in ER + breast cancer.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145572
CAS No.: 2408840-26-4
Purity:  99.02%
Synonyms: LY-3484356
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Imlunestrant (LY-3484356) is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145572A
CAS No.: 2408840-41-3
Purity:  98.54%
Synonyms: LY-3484356 tosylate
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Imlunestrant (LY-3484356) tosylate is an orally active, potent and selective estrogen receptor degrader (SERD) with pure antagonistic properties. Imlunestrant tosylate results in sustained inhibition of ER-dependent gene transcription and cell growth. Imlunestrant tosylate can be used for the research of ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111486
CAS No.: 2135600-76-7
Purity:  99.94%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

LSZ-102 is a potent, orally bioavailable, selective estrogen receptor degrader (SERD) with an IC50 value of 0.2 nM.
loading...
    loading...
Cat. No.: HY-147402A
CAS No.: 2446618-18-2
Purity:  99.98%
Synonyms: D-0502 meglumine
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Taragarestrant (D-0502) meglumine is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant meglumine shows potent activity in various ER+ breast cancer cell lines and xenograft models .
loading...
    loading...
Cat. No.: HY-145341
CAS No.: 1953132-75-6
Purity:  99.18%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

GNE-149 is an orally bioavailable full antagonist of estrogen receptor α (ERα; IC50=0.053 nM). GNE-149 is a selective estrogen receptor degrader (SERD). GNE-149 can be used for the research of breast cancer .
loading...
    loading...
Cat. No.: HY-147402
CAS No.: 2118899-51-5
Synonyms: D-0502
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Taragarestrant (D-0502) is a potent, orally active and selective estrogen receptor degrader (SERD). Taragarestrant shows potent activity in various ER+ breast cancer cell lines and xenograft models .
loading...
    loading...
Cat. No.: HY-125263
CAS No.: 1443752-76-8
Purity:  99.77%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

OP-1074, a pure anti-estrogen drug, is a selective ER degrader (PA-SERD) with specific anti-estrogenic activity against ERα and ERβ, inhibiting 17β-estradiol (E2)-stimulated transcription with IC50 values of 1.6 and 3.2 nM, respectively.
loading...
    loading...
Cat. No.: HY-19822S
Synonyms: RAD1901-d4
Elacestrant-d4 (RAD1901-d4) is a deuterated labeled Elacestrant (HY-19822). Elacestrant (RAD1901) is a selective estrogen receptor (estrogen receptor, ER) degrader (SERD) with oral activity, with IC50 values of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant can also effectively inhibit the growth of ER + breast cancer cell lines both in vitro and in vivo.
loading...
    loading...
Cat. No.: HY-176955
CAS No.: 2376991-14-7
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

ER degrader 12 (Example 1) is an estrogen receptor (ER) degrader with IC50 values for ERα and ERβ of 2.3 and 80.2 nM respectively (TR-FRET experiment). ER degrader 12 inhibits the proliferation of MCF-7 cells, with an IC50 of 1.53 nM. ER degrader 12 can be used for research on breast cancer .
loading...
    loading...
Cat. No.: HY-155492
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

ERα degrader 7 (compound B1) is a potent ERα degrader with an IC50 of 14.6 nM and a DC50 of 9.7 nM, respectively. ERα degrader 7 shows excellent antitumor activity, indicating its potential to evolve as a promising selective estrogen-receptor degrader (SERD) for breast cancer research .
loading...
    loading...
Cat. No.: HY-132194
CAS No.: 2235396-63-9
Purity:  99.71%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

ERα degrader-2 is a selective estrogen receptor degrader (SERD) with potent binding affinity with ERα (IC50=17.1 nM), good degradation efficacy (EC50=0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent agentgability, can be used for HER + breast cancer research .
loading...
    loading...
Cat. No.: HY-101119
CAS No.: 2077980-80-2
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

GLL398 is a potent, orally bioavailable selective estrogen receptor degrader (SERD) with an IC50 value of 1.14 nM. GLL398 shows a strong dose-dependent binding to ER with a mutation at Y537S (IC50=29.5 nM). GLL398 blocks tumor growth in xenograft models of breast cancer.
loading...
    loading...
Cat. No.: HY-144306
CAS No.: 2763464-53-3
Research Areas:  

Cancer

ERα degrader 4 is an excellent and selective estrogen receptor α (ERα) degrader (IC50 of 0.31, 0.41 and 0.48 μM in MDA-MB-231, MCF-7 and MCF-7/ADR cells, respectively). ERα degrader 4 has potent inhibitory activity against MCF-7 cell lines. ERα degrader 4 is a potential SERDs candidate for the research of breast cancer .
loading...
    loading...
Cat. No.: HY-146267
CAS No.: 2941268-96-6
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

ERα degrader 5 (Compound 40) is a selective, orally bioavailable estrogen receptor (ER) degrader (SERD) with an EC50 of 1.1 nM against ERα. ERα degrader 5 shows antitumor effect in vivo .
loading...
    loading...